Advertisement
UK markets close in 31 minutes

  • FTSE 100

    8,307.15
    +93.66 (+1.14%)
     

  • FTSE 250

    20,373.12
    +208.58 (+1.03%)
     

  • AIM

    775.57
    +4.04 (+0.52%)
     

  • GBP/EUR

    1.1646
    -0.0014 (-0.12%)
     

  • GBP/USD

    1.2552
    -0.0012 (-0.09%)
     

  • Bitcoin GBP

    50,815.69
    +277.03 (+0.55%)
     

  • CMC Crypto 200

    1,314.63
    -50.50 (-3.70%)
     

  • S&P 500

    5,195.11
    +14.37 (+0.28%)
     

  • DOW

    38,955.60
    +103.33 (+0.27%)
     

  • CRUDE OIL

    77.75
    -0.73 (-0.93%)
     

  • GOLD FUTURES

    2,328.50
    -2.70 (-0.12%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,398.94
    +223.73 (+1.23%)
     

  • CAC 40

    8,062.76
    +66.12 (+0.83%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

EXCLUSIVE -Shire closer to deal to buy Baxalta -sources

Reuters - UK Focus

NEW YORK, Dec 22 (Reuters) - Drug maker Shire Plc (Xetra: S7E.DE - news) has made a new acquisition offer that is roughly in line with Baxalta International Inc's valuation expectations, making a deal in the coming weeks likely, according to people familiar with the matter.

While the exact terms of the deal could not be learned, Shire has added enough cash to its previous all-stock offer for the negotiations to advance, the people said. Baxalta (Berlin: 9BX.BE - news) would be valued in excess of $30 billion in any deal, one of the people added.

The sources asked not to be identified because the negotiations are confidential. Baxalta and Shire spokespeople offered no comment. (Reporting by Carl O'Donnell in New York and Pamela Barbaglia in London; Editing by James Dalgleish)